Trial
NCT03298048
Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
The University of Texas Health Science Center, Houston
Collaborators
—
Condition
Recurrent C. Difficile Infection
Intervention
Low fecal microbiota dose
Why stopped
Investigators are no longer considering FMT product development for C. difficile.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-06